Novartis AG
ANTI-CD40 ANTIBODIES FOR USE IN TREATMENT OF TIDM AND INSULITIS
Last updated:
Abstract:
The disclosure relates to methods, treatment regimens, uses, kits and therapies for treating T1DM, by employing anti-CD40 antibodies.
Status:
Application
Type:
Utility
Filling date:
6 May 2020
Issue date:
23 Jun 2022